vs
Side-by-side financial comparison of Journey Medical Corp (DERM) and Forward Industries, Inc. (FWDI). Click either name above to swap in a different company.
Forward Industries, Inc. is the larger business by last-quarter revenue ($21.4M vs $16.1M, roughly 1.3× Journey Medical Corp). Journey Medical Corp runs the higher net margin — -7.8% vs -2732.2%, a 2724.4% gap on every dollar of revenue. On growth, Forward Industries, Inc. posted the faster year-over-year revenue change (224.0% vs 27.3%). Over the past eight quarters, Forward Industries, Inc.'s revenue compounded faster (74.6% CAGR vs 11.0%).
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
Melrose Industries plc is a British aerospace manufacturing company based in Birmingham, England. It is the parent company of GKN Aerospace. The company's shares are listed on the London Stock Exchange as a constituent of the FTSE 100 Index.
DERM vs FWDI — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $16.1M | $21.4M |
| Net Profit | $-1.2M | $-585.7M |
| Gross Margin | — | 78.6% |
| Operating Margin | -2.8% | -2722.8% |
| Net Margin | -7.8% | -2732.2% |
| Revenue YoY | 27.3% | 224.0% |
| Net Profit YoY | -182.0% | -82611.5% |
| EPS (diluted) | $-0.04 | $-5.91 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.1M | $21.4M | ||
| Q3 25 | $17.0M | $7.9M | ||
| Q2 25 | $15.0M | $2.5M | ||
| Q1 25 | $13.1M | $3.1M | ||
| Q4 24 | $12.6M | $6.6M | ||
| Q3 24 | $14.6M | — | ||
| Q2 24 | $14.9M | $7.8M | ||
| Q1 24 | $13.0M | $5.1M |
| Q4 25 | $-1.2M | $-585.7M | ||
| Q3 25 | $-2.3M | $-164.0M | ||
| Q2 25 | $-3.8M | $-850.0K | ||
| Q1 25 | $-4.1M | $-1.5M | ||
| Q4 24 | $1.5M | $-708.1K | ||
| Q3 24 | $-2.4M | — | ||
| Q2 24 | $-3.4M | $-399.6K | ||
| Q1 24 | $-10.4M | $-553.2K |
| Q4 25 | — | 78.6% | ||
| Q3 25 | — | 61.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -5.7% | ||
| Q4 24 | 82.3% | 17.1% | ||
| Q3 24 | 63.9% | — | ||
| Q2 24 | 56.0% | 16.8% | ||
| Q1 24 | 47.7% | 26.2% |
| Q4 25 | -2.8% | -2722.8% | ||
| Q3 25 | -9.0% | -39.2% | ||
| Q2 25 | -19.2% | -102.6% | ||
| Q1 25 | -25.3% | -58.3% | ||
| Q4 24 | 17.7% | -13.6% | ||
| Q3 24 | -19.8% | — | ||
| Q2 24 | -19.7% | -5.9% | ||
| Q1 24 | -77.4% | -12.2% |
| Q4 25 | -7.8% | -2732.2% | ||
| Q3 25 | -13.6% | -2063.6% | ||
| Q2 25 | -25.3% | -34.1% | ||
| Q1 25 | -31.0% | -46.5% | ||
| Q4 24 | 12.1% | -10.7% | ||
| Q3 24 | -16.3% | — | ||
| Q2 24 | -22.6% | -5.1% | ||
| Q1 24 | -80.1% | -10.9% |
| Q4 25 | $-0.04 | $-5.91 | ||
| Q3 25 | $-0.09 | $-21.86 | ||
| Q2 25 | $-0.16 | $-0.77 | ||
| Q1 25 | $-0.18 | $-1.32 | ||
| Q4 24 | $0.10 | $-0.64 | ||
| Q3 24 | $-0.12 | — | ||
| Q2 24 | $-0.17 | $-0.36 | ||
| Q1 24 | $-0.53 | $-0.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.1M | — |
| Total DebtLower is stronger | $25.3M | — |
| Stockholders' EquityBook value | $31.9M | $880.9M |
| Total Assets | $94.6M | $892.9M |
| Debt / EquityLower = less leverage | 0.79× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.1M | — | ||
| Q3 25 | $24.9M | — | ||
| Q2 25 | $20.3M | — | ||
| Q1 25 | $21.1M | — | ||
| Q4 24 | $20.3M | — | ||
| Q3 24 | $22.5M | — | ||
| Q2 24 | $23.9M | — | ||
| Q1 24 | $24.1M | — |
| Q4 25 | $25.3M | — | ||
| Q3 25 | $25.2M | — | ||
| Q2 25 | $25.1M | — | ||
| Q1 25 | $25.0M | — | ||
| Q4 24 | $24.9M | — | ||
| Q3 24 | $19.8M | — | ||
| Q2 24 | $19.7M | — | ||
| Q1 24 | $14.7M | — |
| Q4 25 | $31.9M | $880.9M | ||
| Q3 25 | $25.9M | $1.5B | ||
| Q2 25 | $19.2M | $3.4M | ||
| Q1 25 | $21.5M | $3.6M | ||
| Q4 24 | $20.1M | $2.3M | ||
| Q3 24 | $10.9M | — | ||
| Q2 24 | $11.3M | $1.4M | ||
| Q1 24 | $13.0M | $1.8M |
| Q4 25 | $94.6M | $892.9M | ||
| Q3 25 | $85.2M | $1.5B | ||
| Q2 25 | $81.2M | $8.3M | ||
| Q1 25 | $85.0M | $12.3M | ||
| Q4 24 | $80.2M | — | ||
| Q3 24 | $64.0M | — | ||
| Q2 24 | $65.2M | $15.2M | ||
| Q1 24 | $66.6M | $15.2M |
| Q4 25 | 0.79× | — | ||
| Q3 25 | 0.97× | — | ||
| Q2 25 | 1.30× | — | ||
| Q1 25 | 1.16× | — | ||
| Q4 24 | 1.24× | — | ||
| Q3 24 | 1.81× | — | ||
| Q2 24 | 1.75× | — | ||
| Q1 24 | 1.13× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.3M | $-7.9M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.3M | $-7.9M | ||
| Q3 25 | $-2.4M | $-4.5M | ||
| Q2 25 | $-942.0K | $-1.2M | ||
| Q1 25 | $-2.8M | $-537.6K | ||
| Q4 24 | $2.2M | $-434.3K | ||
| Q3 24 | $-1.2M | — | ||
| Q2 24 | $-5.2M | $436.0K | ||
| Q1 24 | $-5.0M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $-4.5M | ||
| Q2 25 | — | $-1.2M | ||
| Q1 25 | — | $-539.0K | ||
| Q4 24 | — | $-439.7K | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $426.8K | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -57.0% | ||
| Q2 25 | — | -50.0% | ||
| Q1 25 | — | -17.3% | ||
| Q4 24 | — | -6.6% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 5.5% | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.3% | ||
| Q2 25 | — | 0.8% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.46× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
FWDI
| CODM | $17.4M | 81% |
| Design Segment | $4.1M | 19% |
